Annual Accounts Receivable
$51.09 M
+$51.09 M+100.00%
31 December 2023
Summary:
TG Therapeutics annual accounts receivable is currently $51.09 million, with the most recent change of +$51.09 million (+100.00%) on 31 December 2023. During the last 3 years, it has risen by +$51.09 million (+100.00%). TGTX annual accounts receivable is now at all-time high.TGTX Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$115.73 M
+$32.12 M+38.42%
30 September 2024
Summary:
TG Therapeutics quarterly accounts receivable is currently $115.73 million, with the most recent change of +$32.12 million (+38.42%) on 30 September 2024. Over the past year, it has increased by +$76.41 million (+194.32%). TGTX quarterly accounts receivable is now at all-time high.TGTX Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TGTX Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +100.0% | +194.3% |
| 3 y3 years | +100.0% | +8261.8% |
| 5 y5 years | - | - |
TGTX Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | at high | ||
| 5 y | 5 years | at high | at high | ||
| alltime | all time | at high | at high |
TG Therapeutics Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $115.73 M(+38.4%) |
| June 2024 | - | $83.61 M(+28.7%) |
| Mar 2024 | - | $64.98 M(+27.2%) |
| Dec 2023 | $51.09 M(>+9900.0%) | $51.09 M(+29.9%) |
| Sept 2023 | - | $39.32 M(+124.9%) |
| June 2023 | - | $17.48 M(+102.8%) |
| Mar 2023 | - | $8.62 M(>+9900.0%) |
| Dec 2022 | $0.00 | $0.00(0.0%) |
| Sept 2022 | - | $0.00(-100.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2022 | - | $88.00 K(-90.3%) |
| Mar 2022 | - | $903.00 K(-35.0%) |
| Dec 2021 | $1.39 M(>+9900.0%) | $1.39 M(+0.4%) |
| Sept 2021 | - | $1.38 M(+48.7%) |
| June 2021 | - | $931.00 K(+20.8%) |
| Mar 2021 | - | $771.00 K(>+9900.0%) |
| Dec 2020 | $0.00(-100.0%) | $0.00(-100.0%) |
| June 2002 | - | $501.70 K(+159.9%) |
| Dec 2000 | $193.00 K(-35.7%) | $193.00 K(-35.7%) |
| Dec 1999 | $300.00 K | $300.00 K |
FAQ
- What is TG Therapeutics annual accounts receivable?
- What is the all time high annual accounts receivable for TG Therapeutics?
- What is TG Therapeutics annual accounts receivable year-on-year change?
- What is TG Therapeutics quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for TG Therapeutics?
- What is TG Therapeutics quarterly accounts receivable year-on-year change?
What is TG Therapeutics annual accounts receivable?
The current annual accounts receivable of TGTX is $51.09 M
What is the all time high annual accounts receivable for TG Therapeutics?
TG Therapeutics all-time high annual accounts receivable is $51.09 M
What is TG Therapeutics annual accounts receivable year-on-year change?
Over the past year, TGTX annual accounts receivable has changed by +$51.09 M (+100.00%)
What is TG Therapeutics quarterly accounts receivable?
The current quarterly accounts receivable of TGTX is $115.73 M
What is the all time high quarterly accounts receivable for TG Therapeutics?
TG Therapeutics all-time high quarterly accounts receivable is $115.73 M
What is TG Therapeutics quarterly accounts receivable year-on-year change?
Over the past year, TGTX quarterly accounts receivable has changed by +$76.41 M (+194.32%)